Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, AXNX is expected to report 3Q20 loss of $ 0.5 per share from revenue of $ 22.95 million.
For the full year, analysts anticipate top line of $ 94.55 million, while looking forward to loss of $ 1.9 per share bottom line.
Previous Quarter Performance
Axonics Modulation Technologies, Inc. posted loss for the second quarter of $ 0.54 per share, from the revenue of $ 15.21 million. The quarterly revenues escalated 920.81 percent compared with the same quarter last year. Street analysts expected Axonics Modulation Technologies, Inc. to report loss of $ 0.65 per share on revenue of $ 5.19 million for the second quarter. The bottom line results beat street analysts by $ 0.11 or 16.92 percent, at the same time, top line results outshined analysts by $ 10.02 million or 193.06 percent.
Stock Performance
Shares of Axonics Modulation Technologies, Inc. traded up $ 2.77 or 6.01 percent on Tuesday, reaching $ 48.83 with volume of 435.20 thousand shares. Axonics Modulation Technologies, Inc. has traded high as $ 50.02 and has cracked $ 46.08 on the downward trend
According to the previous trading day, closing price of $ 48.83, representing a 202.03 % increase from the 52 week low of $ 15.25 and a 11.59 % decrease over the 52 week high of $ 52.10.
The company has a market capital of $ 1.93 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 12th October 2020, maintained by SVB Leerink at Outperform rating, with $ 60.00 target price.
Conference Call
Axonics Modulation Technologies, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.axonicsmodulation.com
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction.
